US Stock MarketDetailed Quotes

MGX Metagenomi Technologies

Watchlist
  • 1.650
  • 0.0000.00%
Close Apr 29 16:00 ET
  • 1.580
  • -0.070-4.24%
Pre 09:25 ET
61.68MMarket Cap-0.79P/E (TTM)

About Metagenomi Technologies Company

Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.

Company Profile

SymbolMGX
Company NameMetagenomi Technologies
Listing DateFeb 9, 2024
Issue Price15.00
Founded2016
CEODr. Brian C. Thomas, PhD
MarketNASDAQ
Employees202
Fiscal Year Ends12-31
Address5959 Horton Street,7th floor
CityEmeryville
ProvinceCalifornia
CountryUnited States of America
Zip Code94608
Phone1-510-871-4880

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Brian C. Thomas, PhD
  • Chief Executive Officer and Chairman of the Board
  • 6.06M
  • Pamela Wapnick, M.B.A.
  • Chief Financial Officer and Principal Accounting Officer
  • 3.58M
  • Dr. Sarah B. Noonberg, M.D.,PhD
  • Chief Medical Officer
  • --
  • Dr. Jian Irish, M.B.A.,PhD
  • President, Chief Operating Officer and Director
  • 3.78M
  • Matthew L. Wein, J.D.
  • Senior Vice President, Head of Legal, Compliance Officer and Corporate Secretary
  • --
  • Eric H. Bjerkholt, M.B.A.
  • Independent Director
  • --
  • Dr. Willard H. Dere, M.D.
  • Lead Independent Director
  • 663.44K
  • Dr. Sebastian Bernales, PhD
  • Independent Director
  • 657.99K
  • Dr. Juergen Eckhardt, M.B.A.,M.D.
  • Independent Director
  • 660.22K

Market Insights

Reassessing Chinese Assets

Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.

Discussing

FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More